Elevated IgM against Nε-(Carboxyethyl)lysine-modified Apolipoprotein A1 peptide 141-147 in Taiwanese with Alzheimer's disease

被引：13

作者：

Lin, Ching-Yu ^{[1
,2
,3
]}

Sheu, Jau-Jiuan ^{[4
,5
]}

Tsai, I-Shih ^{[1
]}

Wang, Sen-Te ^{[6
,7
]}

Yang, Li-Yu ^{[1
]}

Hsu, I-Uen ^{[1
,8
]}

Chang, Hui-Wen ^{[9
]}

Lee, Horng-Mo ^{[1
,2
]}

Kao, Shu-Huei ^{[1
,2
]}

Lee, Ching-Kuo ^{[10
]}

Chen, Chien-Ho ^{[1
,2
]}

Lin, Yung-Feng ^{[1
,2
]}

机构：

[1] Taipei Med Univ, Coll Med Sci & Technol, Sch Med Lab Sci & Biotechnol, Taipei 110, Taiwan

[2] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Med Biotechnol, Taipei 110, Taiwan

[3] Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan 260, Taiwan

[4] Taipei Med Univ Hosp, Dept Neurol, Taipei 110, Taiwan

[5] Taipei Med Univ, Coll Med, Sch Med, Dept Neurol, Taipei 110, Taiwan

[6] Taipei Med Univ, Coll Med, Sch Med, Dept Family Med, Taipei 110, Taiwan

[7] Taipei Med Univ Hosp, Hlth Management Ctr, Taipei 110, Taiwan

[8] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA

[9] Taipei Med Univ Hosp, Dept Lab Med, Taipei 110, Taiwan

[10] Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei 110, Taiwan

来源：

CLINICAL BIOCHEMISTRY | 2018年 / 56卷

关键词：

Alzheimer's disease; Post-translational modification; Advanced glycation end products; ApoA1; CEL; Autoimmunity; GLYCATION END-PRODUCTS; AMYLOID PRECURSOR PROTEIN; BETA; PLASMA; METHYLGLYOXAL; BIOMARKERS;

D O I：

10.1016/j.clinbiochem.2018.04.009

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Objective: Advanced glycation end products (AGEs) are involved in the pathogenesis of Alzheimer's disease (AD). Specific AGEs and related autoantibodies may be early AD markers. Apolipoprotein A1 (ApoA1) and its post-translational modifications (PTMs) are associated with neurodegeneration and thus selected to test the hypothesis. Methods: Serum samples from totally 64 AD or health control (HC) Taiwanese were analyzed. ApoA1 was isolated from the serum and examined through LC-MS/MS and PTM analyses. A specific AGE and its autoantibodies were determined using Western blotting or ELISA. Results: N epsilon-(Carboxyethyl) lysine (CEL) modification, a kind of AGEs, was identified on ApoA1 peptide (141)-QKVEPLR-(147) (ApoA1(141-147)) from AD serum. Total CEL adducts and autoantibodies against CEL on ApoA1(141-147) were significantly increased in AD samples. The area under the receiver operating characteristic curve was 0.965 for anti-CEL-ApoA1(141-147) IgM. Mini Mental State Examination scores of the AD patients were positively correlated with anti-CEL-ApoA1(141-147) IgM, suggesting that the IgM level is high in early AD pathology and decreased with disease progression. Conclusion: CEL modification was increased on AD serum proteins including ApoA1, leading to an elevated anti-CEL IgM in early disease state. Both CEL and anti-CEL IgM may serve as AD biomarkers.

引用

页码：75 / 82

页数：8

共 36 条

[1] Role of Methylglyoxal in Alzheimer's Disease [J].

Angeloni, Cristina ;

Zambonin, Laura ;

Hrelia, Silvana .

BIOMED RESEARCH INTERNATIONAL, 2014, 2014

[2] Role of RAGE in Alzheimer's Disease [J].

Cai, Zhiyou ;

Liu, Nannuan ;

Wang, Chuanling ;

Qin, Biyong ;

Zhou, Yingjun ;

Xiao, Ming ;

Chang, Liying ;

Yan, Liang-Jun ;

Zhao, Bin .

CELLULAR AND MOLECULAR NEUROBIOLOGY, 2016, 36 (04) :483-495

[3] RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain [J].

Deane, R ;

Yan, SD ;

Submamaryan, RK ;

LaRue, B ;

Jovanovic, S ;

Hogg, E ;

Welch, D ;

Manness, L ;

Lin, C ;

Yu, J ;

Zhu, H ;

Ghiso, J ;

Frangione, B ;

Stern, A ;

Schmidt, AM ;

Armstrong, DL ;

Arnold, B ;

Liliensiek, B ;

Nawroth, P ;

Hofman, F ;

Kindy, M ;

Stern, D ;

Zlokovic, B .

NATURE MEDICINE, 2003, 9 (07) :907-913

[4]

Desai Kaushik M., 2008, Drug Metabolism and Drug Interactions, V23, P151

[5] High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes [J].

Engelbertsen, D. ;

Anand, D. V. ;

Fredrikson, G. N. ;

Hopkins, D. ;

Corder, R. ;

Shah, P. K. ;

Lahiri, A. ;

Nilsson, J. ;

Bengtsson, E. .

JOURNAL OF INTERNAL MEDICINE, 2012, 271 (01) :82-89

[6] The AD8 - A brief informant interview to detect dementia [J].

Galvin, JE ;

Roe, CM ;

Powlishta, KK ;

Coats, MA ;

Muich, SJ ;

Grant, E ;

Miller, JP ;

Storandt, M ;

Morris, JC .

NEUROLOGY, 2005, 65 (04) :559-564

[7] AMYLOID-BETA BINDING-PROTEINS IN-VITRO AND IN NORMAL HUMAN CEREBROSPINAL-FLUID [J].

GOLABEK, A ;

MARQUES, MA ;

LALOWSKI, M ;

WISNIEWSKI, T .

NEUROSCIENCE LETTERS, 1995, 191 (1-2) :79-82

[8] PeaksPTM: Mass Spectrometry-Based Identification of Peptides with Unspecified Modifications [J].

Han, Xi ;

He, Lin ;

Xin, Lei ;

Shan, Baozhen ;

Ma, Bin .

JOURNAL OF PROTEOME RESEARCH, 2011, 10 (07) :2930-2936

[9] The future of blood-based biomarkers for Alzheimer's disease [J].

Henriksen, Kim ;

O'Bryant, Sid E. ;

Hamper, Harald ;

Trojanowski, John Q. ;

Montine, Thomas J. ;

Jeromin, Andreas ;

Blennow, Kaj ;

Lonneborg, Anders ;

Wyss-Coray, Tony ;

Soares, Holly ;

Bazenet, Chantal ;

Sjogren, Magnus ;

Hu, William ;

Lovestone, Simon ;

Karsdal, Morten A. ;

Weiner, Michael W. .

ALZHEIMERS & DEMENTIA, 2014, 10 (01) :115-131

[10] Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy [J].

Jack, Megan ;

Wright, Douglas .

TRANSLATIONAL RESEARCH, 2012, 159 (05) :355-365

← 1 2 3 4 →